8-K · latest 10
What Amgen's 8-K filings say
- SEC EDGAR
8-K
Filed · 2 signals
Amgen confirms restructuring, cost-saving initiatives, and employee terminations in Q2 2026 report.
Amgen is actively engaged in restructuring and cost-saving initiatives that include employee severance as part of its 'transformation and process improvement efforts'.
- SEC EDGAR
8-K
Filed · 1 signal
Amgen rejects shareholder proposal for an independent board chairman amid governance scrutiny
Amgen's board defeated a shareholder proposal to require an independent chairman, despite over 72.9 million votes in favor.
Ernst & Young LLP
- SEC EDGAR
8-K
Filed · 3 signals
Amgen appoints Thomas Dittrich as new CFO effective Sept 1, 2026, replacing retiring Peter Griffith.
Mr. Dittrich's experience leading a 'company-wide transformation program' at his prior company suggests a high probability of new initiatives and budget re-evaluation at Amgen.
$14.8M
Total one-time cash, RSU, retention, and relocation bonuses (in CHF) to hire new CFO Thomas Dittrich.
ITTakeda Pharmaceutical Company
- SEC EDGAR
8-K
Filed · 2 signals
Amgen discloses ongoing restructuring and cost-saving initiatives impacting facilities and staff.
The company is incurring costs for facility charges, asset impairments, and employee severance as part of its transformation and process improvement efforts.
- SEC EDGAR
8-K
Filed · 3 signals
The retirement of CTO David M. Reese and the elimination of the CTO position signals a major strategic shift in how Amgen integrates technology, data, and AI with its commercial and financial operations.
Artificial IntelligenceData
The elimination of the dedicated CTO role signals a major strategic shift, embedding technology decisions directly within R&D/AI, Global Markets, and Finance.
Artificial IntelligenceData
- SEC EDGAR
8-K
Filed · 3 signals
Amgen secured approximately $3.96 billion in net proceeds from a multi-tranche senior notes offering.
$4B
Net proceeds from senior notes offering
BofA Securities, Inc.Citigroup Global Markets Inc.J.P. Morgan Securities LLCMorgan Stanley & Co. LLC
- SEC EDGAR
8-K
Filed · 2 signals
The company is actively engaged in 'transformation and process improvement efforts' that include employee severance and facilities-related charges.
- SEC EDGAR
8-K
Filed · 2 signals
This termination of a multi-year collaboration signals a significant strategic pivot, potentially creating needs for new partners, internal resource reallocation, or alternative solutions to fill the gap left by the dissolved partnership.
Kyowa Kirin Co., Ltd.
Amgen terminates material license and collaboration agreement with Kyowa Kirin dated June 2021.
This termination of a key partnership signals a significant strategic shift, potentially freeing up or requiring reallocation of resources.
Kyowa Kirin Co., Ltd.
Showing 10 of 18 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Amgen with the Signal API
One POST /v1/companies/enrich call with amgen.com returns Amgen 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"amgen.com","signal_types":["sec-8k"],"limit":20}'Same industry
8-K at related companies
Questions about Amgen 8-K
When did Amgen file its latest 8-K?
What did Amgen disclose in its latest 8-K?
Where can I read Amgen's 8-K filing?
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .